Hasil Pencarian - David A. Sallman

Perbaiki Hasil
  1. 1
    To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia

    To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia oleh David A. Sallman

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The role of innate immunity in MDS pathogenesis

    The role of innate immunity in MDS pathogenesis oleh David A. Sallman, Alan List

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Myelodysplasia in younger adults: outlier or unique molecular entity?

    Myelodysplasia in younger adults: outlier or unique molecular entity? oleh David A. Sallman, Eric Padron

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes

    Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes oleh Joseph A. Clara, David A. Sallman, Eric Padron

    Diterbitkan 2016-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

    Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia oleh Thomas Cluzeau, Michael Loschi, Pierre Fenaux, Rami Komrokji, David A. Sallman

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

    Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) oleh Andrew M. Brunner, Alexander Gavralidis, Najla Al Ali, Anthony Hunter, Rami Komrokji, Amer Zeidan, David A. Sallman

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    <i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

    <i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy oleh Rami Komrokji, Najla al Ali, Onyee Chan, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David A. Sallman

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Integrative molecular subtypes of acute myeloid leukemia

    Integrative molecular subtypes of acute myeloid leukemia oleh Qianxing Mo, Seongseok Yun, David A. Sallman, Nicole D. Vincelette, Guang Peng, Ling Zhang, Jeffrey E. Lancet, Eric Padron

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)

    P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) oleh Lisa Johnson, Yajia Zhang, Linda Su-Feher, Yeonju Lee, David A. Sallman, Adam S. Asch, Monzr M. Al Malki, Hyunjae Ryan Kim

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

    Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome oleh Rami S. Komrokji, Avani M. Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E. Lancet, David A. Sallman

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

    NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient oleh David A. Sallman, Jason Brayer, Elizabeth M. Sagatys, Caroline Lonez, Eytan Breman, Sophie Agaugué, Bikash Verma, David E. Gilham, Frédéric F. Lehmann, Marco L Davila

    Diterbitkan 2018-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia

    Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia oleh Akriti G. Jain, Somedeb Ball, Luis Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami Komrokji

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning

    Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning oleh David A. Sallman, Rafael Bejar, Guillermo Montalban-Bravo, Sandra E. Kurtin, Alan F. List, Guillermo Garcia-Manero, Stephen D. Nimer, Casey L. O'Connell, Dale Schaar, Janice Butchko, Tracey Iraca, Stephanie Searle

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

    Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin oleh Chen Wang, Kathy L. McGraw, Amy F. McLemore, Rami Komrokji, Ashley A. Basiorka, Najla Al Ali, Jeffrey E. Lancet, Eric Padron, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Alan F. List, David A. Sallman

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes

    Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes oleh Amy F. McLemore, Hsin-An Hou, Benjamin S. Meyer, Nghi B. Lam, Grace A. Ward, Amy L. Aldrich, Matthew A. Rodrigues, Alexis Vedder, Ling Zhang, Eric Padron, Nicole D. Vincelette, David A. Sallman, Omar Abdel-Wahab, Alan F. List, Kathy L. McGraw

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

    A machine learning model of response to hypomethylating agents in myelodysplastic syndromes oleh Nathan Radakovich, David A. Sallman, Rena Buckstein, Andrew Brunner, Amy Dezern, Sudipto Mukerjee, Rami Komrokji, Najla Al-Ali, Jacob Shreve, Yazan Rouphail, Anne Parmentier, Alexandre Mamedov, Mohammed Siddiqui, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal Jha, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Aziz Nazha

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

    Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia oleh Catherine C. Coombs, David A. Sallman, Sean M. Devlin, Shweta Dixit, Abhinita Mohanty, Kristina Knapp, Najla H. Al Ali, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji, Eric Padron, Maria E. Arcila, Virginia M. Klimek, Marcel R. M. van den Brink, Martin S. Tallman, Ross L. Levine, Raajit K. Rampal, Franck Rapaport

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Examining disparities in large‐scale patient‐reported data capture using digital tools among cancer patients at clinical intake

    Examining disparities in large‐scale patient‐reported data capture using digital tools among cancer patients at clinical intake oleh Dana E. Rollison, Brian D. Gonzalez, Kea Turner, Heather S. L. Jim, Yayi Zhao, Rossybelle P. Amorrortu, Rachel Howard, Kavita M. Ghia, Bryan Ngo, Phillip Reisman, Colin Moore, Randa Perkins, Robert J. Keenan, David A. Sallman, Cristina M. Naso, Edmondo J. Robinson, Susan T. Vadaparampil, Vani N. Simmons, Matthew B. Schabath, Scott M. Gilbert

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

    Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis oleh Kathy L. McGraw, Chia-Ho Cheng, Y. Ann Chen, Hsin-An Hou, Björn Nilsson, Giulio Genovese, Thomas Cluzeau, Andrea Pellagatti, Bartlomiej P. Przychodzen, Mar Mallo, Leonor Arenillas, Azim Mohamedali, Lionel Adès, David A. Sallman, Eric Padron, Lubomir Sokol, Chimene Moreilhon, Sophie Raynaud, Hwei-Fang Tien, Jacqueline Boultwood, Benjamin L. Ebert, Francesc Sole, Pierre Fenaux, Ghulam J. Mufti, Jaroslaw P. Maciejewski, Peter A. Kanetsky, Alan F. List

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

    Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the Internatio... oleh Fabio Efficace, Rena Buckstein, Gregory A. Abel, Johannes M. Giesinger, Pierre Fenaux, Jan Philipp Bewersdorf, Andrew M. Brunner, Rafael Bejar, Uma Borate, Amy E. DeZern, Peter Greenberg, Gail J. Roboz, Michael R. Savona, Francesco Sparano, Jacqueline Boultwood, Rami Komrokji, David A. Sallman, Zhuoer Xie, Guillermo Sanz, Hetty E. Carraway, Justin Taylor, Stephen D. Nimer, Matteo Giovanni Della Porta, Valeria Santini, Maximilian Stahl, Uwe Platzbecker, Mikkael A. Sekeres, Amer M. Zeidan

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: